Last reviewed · How we verify

Civamide — Competitive Intelligence Brief

Civamide (Civamide) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Other.

discontinued Transient receptor potential cation channel subfamily V member 1 Other Small molecule Live · refreshed every 30 min

Target snapshot

Civamide (Civamide) — Winston Laboratories.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Civamide TARGET Civamide Winston Laboratories discontinued Transient receptor potential cation channel subfamily V member 1
Qutenza CAPSAICIN Averitas marketed capsaicin Transient receptor potential cation channel subfamily V member 1 2009-01-01
Cortisporin NEOMYCIN Pfizer marketed Aminoglycoside Antibacterial Transient receptor potential cation channel subfamily V member 1 1957-01-01
Neomycin B FRAMYCETIN phase 3 framycetin Lecithin retinol acyltransferase, Menin, Transient receptor potential cation channel subfamily V member 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Civamide — Competitive Intelligence Brief. https://druglandscape.com/ci/civamide. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: